As of 2026-10-10, the Relative Valuation of Cymabay Therapeutics Inc (CBAY) is (11.68) USD. This relative valuation is based on P/E multiples. With the latest stock price at 32.48 USD, the upside of Cymabay Therapeutics Inc based on Relative Valuation is -136.0%.
The range of the Relative Valuation is (7.78) - (15.55) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 19.8x | 12.5x |
| Forward P/E multiples | 8.5x - 16.9x | 13.0x |
| Fair Price | (7.78) - (15.55) | (11.68) |
| Upside | -124.0% - -147.9% | -136.0% |
| Date | P/E |